Double antiagrégation plaquettaire pour le traitement et la prévention secondaire de la maladie coronarienne. Indications, modalités et durées de traitement [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
Serval ID
serval:BIB_AE3B2E49E3E0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Double antiagrégation plaquettaire pour le traitement et la prévention secondaire de la maladie coronarienne. Indications, modalités et durées de traitement [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
Journal
Revue Medicale Suisse
Author(s)
Degrauwe S., Iglesias J.F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2016
Volume
12
Number
520
Pages
1022-6, 1028-34
Language
french
Notes
Publication types: English Abstract ; Journal Article ; ReviewPublication Status: ppublish
Abstract
The choice and optimal duration of dualantiplatelet therapy (DAPT) for the treatment of coronary artery disease (CAD) represent a challenging clinical dilemma. Antiplatelet treatment strategies are determined by the clinical setting, patient comorbidities and management strategy. While aspirin remains the cornerstone for secondary prevention of CAD, DAPT significantly reduces recurrent ischemic adverse events at the expense of an increased risk of major bleeding complications. A tailored approach based on individual ischemic and hemorrhagic risk assessment is currently recommended. This review aims to provide a contemporary overview on the current body of evidence concerning DAPT for treatment and secondary prevention of CAD with practical emphasis on current indications, choice, combination and optimal duration of antiplatelet therapy.
Keywords
Aspirin/administration & dosage, Aspirin/adverse effects, Coronary Artery Disease/drug therapy, Coronary Artery Disease/prevention & control, Drug Therapy, Combination, Hemorrhage/chemically induced, Humans, Platelet Aggregation Inhibitors/administration & dosage, Platelet Aggregation Inhibitors/adverse effects, Risk Assessment/methods, Secondary Prevention/methods, Time Factors
Pubmed
Create date
19/10/2016 14:45
Last modification date
20/08/2019 16:18
Usage data